A Modified Cell-Penetrating Peptide Enhances Insulin and Oxytocin Delivery across an RPMI 2650 Nasal Epithelial Cell Barrier In Vitro
<b>Background/Objectives:</b> Peptide-based treatments represent an expanding area and require innovative approaches to enhance bioavailability. Combination with cell-penetrating peptides (CPPs) is an attractive strategy to improve non-invasive delivery across nasal epithelial barriers f...
Saved in:
Main Authors: | Sara Wong (Author), Alexander D. Brown (Author), Abigail B. Abrahams (Author), An Nisaa Nurzak (Author), Hoda M. Eltaher (Author), David A. Sykes (Author), Dmitry B. Veprintsev (Author), Kevin C. F. Fone (Author), James E. Dixon (Author), Madeleine V. King (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Applicability of RPMI 2650 and Calu-3 Cell Models for Evaluation of Nasal Formulations
by: Nadica Sibinovska, et al.
Published: (2022) -
Improved In Vitro Model for Intranasal Mucosal Drug Delivery: Primary Olfactory and Respiratory Epithelial Cells Compared with the Permanent Nasal Cell Line RPMI 2650
by: Simone Ladel, et al.
Published: (2019) -
Investigation of the inhibitory effects of simvastatin in RPMI 2650: an in-vitro study / Jaapar K. H. ... [et al.]
by: Jaapar, K.H, et al.
Published: (2022) -
The Development of an In Vitro Horizontal Diffusion Cell to Monitor Nasal Powder Penetration Inline
by: Péter Gieszinger, et al.
Published: (2021) -
Systemic and brain delivery of antidiabetic peptides through nasal administration using cell-penetrating peptides
by: Jeehye Maeng, et al.
Published: (2022)